0000000000928251

AUTHOR

Giovanni Franco

showing 16 related works from this author

The bone marrow stroma in hematological neoplasms—a guilty bystander

2011

In the setting of hematological neoplasms, changes in the bone marrow (BM) stroma might arise from pressure exerted by the neoplastic clone in shaping a supportive microenvironment, or from chronic perturbation of the BM homeostasis. Under such conditions, alterations in the composition of the BM stroma can be profound, and could emerge as relevant prognostic factors. In this Review, we delineate the multifaceted contribution of the BM stroma to the pathobiology of several hematological neoplasms, and discuss the impact of stromal modifications on the natural course of these diseases. Specifically, we highlight the involvement of BM stromal components in lymphoid and myeloid malignancies, a…

Pathologymedicine.medical_specialtyMyeloidStromal cellbusiness.industrymedicine.diseaseArticleLymphomaBone marrow stroma hematological neoplasmsmedicine.anatomical_structureOncologyStromaBone MarrowHematologic NeoplasmsmedicineBystander effectAnimalsHumansHematological neoplasmBone marrowStromal CellsbusinessHomeostasisNature Reviews Clinical Oncology
researchProduct

Challenges and new prospects in hepatosplenic γδ T-cell lymphoma.

2014

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid neoplasms characterized by aggressive clinical behavior and dismal prognosis. Hepatosplenic γδ T-cell lymphoma (γδ-HSTL) is a particular form of PTCL that arises from a small subset of γ/δ T-cell receptor-expressing lymphocytes. γδ-HSTL has a rapidly progressive course and poor outcome due also to its refractoriness to conventional chemotherapy regimens. The very low incidence of γδ-HSTL, along with its propensity to mimic different pathological entities, makes this lymphoma a true diagnostic challenge. In this review, we highlight the biological and clinical features of γδ-HSTL that contribute to making this lymphoma…

Cancer ResearchHepatosplenic T-cell lymphomaSpleenDiseaseBiologyT cell lymphomaAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansT-cell lymphomaPathologicalgamma delta T cell lymphomahepatosplenic T cell lymphomaSplenic NeoplasmsLiver NeoplasmsLymphoma T-Cell PeripheralReceptors Antigen T-Cell gamma-deltaHematologymedicine.diseaseCombined Modality Therapyperipheral T cell lymphomasLymphomaT cell lymphoma; gamma delta T cell lymphomas; hepatosplenic T cell lymphoma; peripheral T cell lymphomasTreatment Outcomemedicine.anatomical_structureOncologyImmunologyConventional chemotherapyBone marrowStem Cell Transplantation
researchProduct

T Cell Large Granular Lymphocytic Leukemia in Association with Sjögren’s Syndrome

2009

T cell large granular lymphocytic (LGL) leukemia is a rare condition accounting for 2–3% of all mature lymphoid leukemias. Here, we present the case of a 73-year-old woman presenting with neutropenia and anemia (hemoglobin 9.9 g/dl). Hematological assessment revealed the presence of a T cell LGL leukemia. At the time of T cell LGL leukemia diagnosis, the patient developed xerophthalmia and xerostomia, and a diagnosis of Sjögren’s syndrome was made following salivary gland biopsy. The finding of large granular lymphocytes in the context of autoimmune disorders is well-known, though it often occurs with rheumatoid arthritis or in association with a positive autoantibody titer in the absence o…

LGL leukemiaNeutropeniaT cellchemical and pharmacologic phenomenaContext (language use)Settore MED/08 - Anatomia PatologicaNeutropeniamedicine.disease_causeAutoimmune DiseasesSettore MED/15 - Malattie Del SangueAutoimmunityhemic and lymphatic diseasesmedicineHumansAgedbusiness.industryAutoantibodyAnemiaHematologyGeneral Medicinemedicine.diseaseLymphomaLeukemia Large Granular LymphocyticLeukemiaSjogren's Syndromemedicine.anatomical_structureRheumatoid arthritisImmunologyFemalebusinessImmunosuppressive AgentsActa Haematologica
researchProduct

Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma

2010

Reports focusing on the immunological microenvironment of peripheral T-cell lymphomas (PTCL) are rare. Here we studied the reciprocal contribution of regulatory (Treg) and interleukin-17-producing (Th17) T-cells to the composition of the lymphoma-associated microenvironment of angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified on tissue microarrays from 30 PTCLs not otherwise specified and 37 AITLs. We found that Th17 but not Treg cells were differently represented in the two lymphomas and correlated with the amount of mast cells (MCs) and granulocytes, which preferentially occurred in the cellular milieu of AITL cases. We observed that MCs directly synthesized inter…

Angioimmunoblastic T-cell lymphomaLymphomaInflammationBiologymedicine.disease_causeCXCR3Lymphoma T-CellCXCR5Pathology and Forensic MedicineAutoimmunityAnimals Chemokine CXCL13; immunology Cytokines; genetics/immu/nology Forkhead Transcription Factors; immunology Gene Expression Profiling Humans Immunoblastic Lymphadenopathy; immunology/pathology Inflammation; immunology Interleukin-17; immunology Interleukin-6; immunology Lymphoma; T-Cell; immunology/pathology Mast Cells; immunology Microarray Analysis Th17 Cells; immunology Tumor MicroenvironmentimmunologymedicineTumor MicroenvironmentAnimalsHumansMast CellsInflammationTumor microenvironmentInterleukin-6Gene Expression ProfilingInterleukin-17Forkhead Transcription FactorsMast cellmedicine.diseaseT-CellMicroarray AnalysisChemokine CXCL13humanitiesgenetics/immu/nologyLymphomamedicine.anatomical_structureImmunoblastic LymphadenopathyImmunologyCytokinesimmunology/pathologyTh17 CellsMast Cell microenvironment angioimmunoblasticmedicine.symptomRegular Articles
researchProduct

Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion.

2012

Abstract In myeloid malignancies, the neoplastic clone outgrows normal hematopoietic cells toward BM failure. This event is also sustained by detrimental stromal changes, such as BM fibrosis and osteosclerosis, whose occurrence is harbinger of a dismal prognosis. We show that the matricellular protein SPARC contributes to the BM stromal response to myeloproliferation. The degree of SPARC expression in BM stromal elements, including CD146+ mesenchymal stromal cells, correlates with the degree of stromal changes, and the severity of BM failure characterizing the prototypical myeloproliferative neoplasm primary myelofibrosis. Using Sparc−/− mice and BM chimeras, we demonstrate that SPARC contr…

AdultMalePathologymedicine.medical_specialtyMyeloidStromal cellImmunologyAdenomatous Polyposis Coli ProteinGene ExpressionCD146 AntigenBiologyBiochemistryMiceBone MarrowMyeloproliferationmedicineAnimalsHumansMyeloid CellsOsteonectinMyelofibrosisMyeloproliferative neoplasmCells CulturedAgedCell ProliferationAged 80 and overMice KnockoutMesenchymal stem cellMesenchymal Stem CellsPMF SPARC MYELOFIBROSISCell BiologyHematologyMiddle Agedmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureThrombopoietinLeukemia MyeloidPrimary MyelofibrosisFemaleSPARC stroma
researchProduct

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

2014

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone geneticsandthe recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic rele…

MalePathologyBiochemistryMiceTumor MicroenvironmentMast CellMedicineMast CellsInflammation MediatorAged 80 and overMice KnockoutB-LymphocytesMice Inbred BALB CMesenchymal Stromal CellB-LymphocyteCD40 AntigenCell DifferentiationHematologyMiddle AgedPrognosismedicine.anatomical_structureDisease ProgressionCytokinesFemaleInflammation MediatorsClone (B-cell biology)HumanAdultmedicine.medical_specialtyStromal cellPrognosiCD40 LigandImmunologyDisease-Free SurvivalAnimalsHumansSplenic marginal zone lymphomaCD40 AntigensCytokineB cellAgedCell ProliferationAnimalbusiness.industryMesenchymal stem cellMesenchymal Stem CellsLymphoma B-Cell Marginal ZoneCell BiologyGenes p53medicine.diseaseLymphomaSplenic marginal zone lymphoma bone marrow microenvironment CD40Mast cell sarcomaBone marrowbusinessBlood
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct

CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis

2008

Abstract CD146+ bone marrow stromal cells have been recently recognized as clonogenic osteoprogenitors able to organize a complete hematopoietic microenvironment. In this study we used immunohistochemical analysis to investigate the contribution of CD146+ bone marrow osteoprogenitors to the stromal remodeling occurring in the different stages of primary myelofibrosis. We found that CD146+ cells sited at the abluminal side of the bone marrow vessels and branching among hematopoietic cells significantly increased in the advanced stages of primary myelofibrosis (p<0.001), paralleling the extent of fibrosis (r=0.916, p<0.0001) and the microvascular density (r=0.883, p<0.0001). Coherently with a…

AdultMalebone marrow stromal cellmedicine.medical_specialtyPathologyStromal cellAngiogenesisBone Marrow CellsCD146 AntigenBiologyMural cellInternal medicinemedicineHumansMyelofibrosisAgedCell ProliferationNeoplasm StagingAged 80 and overHematologyCD146; bone marrow stromal cells; primary myelofibrosisStem CellsHematologyMiddle Agedmedicine.diseaseHaematopoiesismedicine.anatomical_structureCD146Primary MyelofibrosisBrief ReportsFemaleBone marrowStem cell
researchProduct

The bone marrow stroma in hematological neoplasms-a guilty bystander.

2011

In the setting of hematological neoplasms, changes in the bone marrow (BM) stroma might arise from pressure exerted by the neoplastic clone in shaping a supportive microenvironment, or from chronic perturbation of the BM homeostasis. Under such conditions, alterations in the composition of the BM stroma can be profound, and could emerge as relevant prognostic factors. In this Review, we delineate the multifaceted contribution of the BM stroma to the pathobiology of several hematological neoplasms, and discuss the impact of stromal modifications on the natural course of these diseases. Specifically, we highlight the involvement of BM stromal components in lymphoid and myeloid malignancies, a…

hematological malignancies.bone marrow stroma
researchProduct

Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange

2012

Settore MED/04 - Patologia Generalethrombotic thrombocytopenic purpura ADAMTS 13 plasma exchange therapy
researchProduct

Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

2009

chronic myeloid leukemia secondary malignancySettore MED/15 - Malattie Del Sangue
researchProduct

Comparison between whole-body MRI and PET/CT in staging newly diagnosed FDG-avid lymphomas: our experience.

2015

To compare whole body RMI (WB-RMI) and FDG-PET/CT for staging newly diagnosed FDG-avid lymphoma

Magnetic resonance imagingLymphomaStaging.Diffusion-weighted imagingPositron-emission tomographySettore MED/36 - Diagnostica Per Immagini E RadioterapiaComputed tomography
researchProduct

BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA

2010

At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresses

splenic marginal zone lymphomabendamustineSettore MED/15 - Malattie Del Sangue
researchProduct

Lymphonodal amyloidosis: case report

2009

Amyloidosis lymphomaSettore MED/15 - Malattie Del Sangue
researchProduct

Chronic myeloid leukemia as second malignancy; restrospective multicentric study

2009

chronic myeloid leukemia second malignancySettore MED/15 - Malattie Del Sangue
researchProduct

PNEUMOCYSTIS JIROVECI PNEUMONIA IN HEMATOLOGICAL PATIENTS: A SINGLE INSTITUTION EXPERIENCE

2012

PJP infection Haematological neoplasmsSettore MED/15 - Malattie Del Sangue
researchProduct